Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|July 16, 2005
Aromatase inhibitors: future directionsC Kent Osborne, Rachel Schiff
The New England Journal of Medicine|March 15, 2013
Circulating tumor DNA--ready for prime time?Marc Lippman, C Kent Osborne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2005
Estrogen-receptor biology: continuing progress and therapeutic implicationsC Kent Osborne, Rachel Schiff
Breast (Edinburgh, Scotland)|December 9, 2003
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancerC Kent Osborne, Rachel Schiff
Breast Cancer Research : BCR|September 20, 2005
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerRachel Schiff, C Kent Osborne
Annual Review of Medicine|October 5, 2010
Mechanisms of endocrine resistance in breast cancerC Kent Osborne, Rachel Schiff
Oncology (Williston Park, N.Y.)|February 15, 2012
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual MeetingC Kent Osborne, Andrew Evens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Role of molecular and genetic markers in breast cancer treatment decisionsC Kent Osborne, Carlos L Arteaga
Nature Reviews. Clinical Oncology|February 15, 2012
Breast Cancer: Blocking both driver and escape pathways improves outcomesMothaffar F Rimawi, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trialSusan G Hilsenbeck, C Kent Osborne
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
The Journal of Steroid Biochemistry and Molecular Biology|July 16, 2005
Aromatase inhibitors: future directionsC Kent Osborne, Rachel Schiff
The New England Journal of Medicine|March 15, 2013
Circulating tumor DNA--ready for prime time?Marc Lippman, C Kent Osborne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2005
Estrogen-receptor biology: continuing progress and therapeutic implicationsC Kent Osborne, Rachel Schiff
Breast (Edinburgh, Scotland)|December 9, 2003
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancerC Kent Osborne, Rachel Schiff
Breast Cancer Research : BCR|September 20, 2005
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerRachel Schiff, C Kent Osborne
Annual Review of Medicine|October 5, 2010
Mechanisms of endocrine resistance in breast cancerC Kent Osborne, Rachel Schiff
Oncology (Williston Park, N.Y.)|February 15, 2012
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual MeetingC Kent Osborne, Andrew Evens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Role of molecular and genetic markers in breast cancer treatment decisionsC Kent Osborne, Carlos L Arteaga
Nature Reviews. Clinical Oncology|February 15, 2012
Breast Cancer: Blocking both driver and escape pathways improves outcomesMothaffar F Rimawi, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trialSusan G Hilsenbeck, C Kent Osborne
Pageof 16